[1] |
Raghu G, Collard R, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183(6):788-824.
|
[2] |
Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11[J]. Lancet Respir Med, 2014, 2(7):566-572.
|
[3] |
Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK[J]. Adv The, 2018, 35(5):724-736.
|
[4] |
Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50(1):3-13.
|
[5] |
周惠琼,张奉春.涎液化糖链抗原-6在间质性肺疾病诊疗中的价值[J].协和医学杂志,2018,9(3):207-212.
|
[6] |
Bennett D, Salvini M, Fui A, et al. Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP[J]. Inflammation, 2019, 42(2):463-470.
|
[7] |
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS /ERS /JRS /ALAT clinical practice guideline[J]. Am J Respir Crit Care Med, 2018, 198(5):e44-e68.
|
[8] |
Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report[J]. Am J Respir Crit Care Med, 2016, 194(3):265-275.
|
[9] |
中华医学会呼吸病学分会间质性肺病学组,中国医师协会呼吸医师分会间质性肺疾病工作委员会.特发性肺纤维化急性加重诊断和治疗中国专家共识[J].中华医学杂志,2019,99(26):2014-2023.
|
[10] |
Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6[J]. Chest, 1989, 96(1):68-73.
|
[11] |
Xu L, Yan DR, Zhu SL, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation[J]. Eur Rev Med Pharmacol Sci, 2013, 17(22):3073-3077.
|
[12] |
Ohshimo S, Yokoyama A, Hattori N, et al. KL-6, ahuman MUC1/mucin, promotes proliferation and survival of lung fibroblasts[J]. Bio Chem Biophys Res Commun, 2005, 338(4):1845-1852.
|
[13] |
Yamakawa H, Hagiwara E, Kitamura H, et al. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease[J]. Thorac Dis, 2017, 9(2):362-371.
|
[14] |
朱晨,赵亚斌,孔灵菲,等.涎液化糖链抗原-6在不同类型的弥漫性问质性肺疾病患者血清和支气管肺泡灌洗液中的表达及临床意义[J].中华结核和呼吸杂志,2016,39(2):93-97.
|
[15] |
Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis[J]. Am J Physiol Lung Cell Mol Physiol, 2010, 299(1):L3-L7.
|
[16] |
Okamoto M. Periostin, a matrix protein, is a novel biomarker foridiopathic interstitial pneumonias[J]. Eur Respir J, 2011, 37(5):1119.
|
[17] |
Kai W, Ju Q, Jing C, et al. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J]. Medicine(Baltimore), 2017, 96(23):e7083.
|
[18] |
Kakugawa T, Yokota S, Ishimatsu Y, et al. Serum heat shockprotein 47 levels are elevated in acute exacerbation of idiopathicpulmonary fibrosis[J]. Cell Stress Chaperones, 2013, 18(5):581-590.
|
[19] |
Barratt SL, Creamer A, Hayton C, et al. Idiopathic pulmonary fibrosis (IPF): An overview[J]. J Clin Med, 2018, 7(8):201.
|
[20] |
任登华,丁晶晶,蔡后荣.血清KL-6水平在间质性肺疾病诊断中的价值研究[J].中国呼吸与危重症杂志,2015,14(5):468-473.
|
[21] |
张建,范利,华琦,等.老年医学[M].2版.北京:人民卫生出版社,2014:158-162.
|